Literature DB >> 17989186

Extending the cytoplasmic tail of the influenza a virus M2 protein leads to reduced virus replication in vivo but not in vitro.

Wai-Hong Wu1, Andrew Pekosz.   

Abstract

A carboxy-terminal epitope tag introduced into the coding region of the A/WSN/33 M2 protein resulted in a recombinant virus (rWSN M2myc) which replicated to titers similar to those of the parental virus (rWSN) in MDCK cells. The rWSN M2myc virus was attenuated in its ability to induce mortality and weight loss after the intranasal inoculation of BALB/c mice, indicating that the M2 cytoplasmic tail plays a role in virus virulence. Mice infected with rWSN M2myc were completely protected from subsequent challenge with rWSN, suggesting that epitope tagging of the M2 protein may be a useful way of attenuating influenza A virus strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989186      PMCID: PMC2224589          DOI: 10.1128/JVI.01499-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  Overview of avian influenza DIVA test strategies.

Authors:  David L Suarez
Journal:  Biologicals       Date:  2005-10-28       Impact factor: 1.856

2.  A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin.

Authors:  J Stech; H Garn; M Wegmann; R Wagner; H-D Klenk
Journal:  Nat Med       Date:  2005-05-29       Impact factor: 53.440

3.  Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production.

Authors:  Matthew F McCown; Andrew Pekosz
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters.

Authors:  Celeste M Newby; Regina K Rowe; Andrew Pekosz
Journal:  Virology       Date:  2006-07-31       Impact factor: 3.616

Review 5.  Controlling influenza virus replication by inhibiting its proton channel.

Authors:  Lawrence H Pinto; Robert A Lamb
Journal:  Mol Biosyst       Date:  2006-11-22

6.  The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging.

Authors:  Matthew F McCown; Andrew Pekosz
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Takeshi Noda; Maki Kiso; Junko Maeda; Shinji Watanabe; Yukiko Muramoto; Ken Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells.

Authors:  Aida Ibricevic; Andrew Pekosz; Michael J Walter; Celeste Newby; John T Battaile; Earl G Brown; Michael J Holtzman; Steven L Brody
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

9.  Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.

Authors:  M Elizabeth Halloran; Pedro A Piedra; Ira M Longini; Manjusha J Gaglani; Brian Schmotzer; Charles Fewlass; Gayla B Herschler; W Paul Glezen
Journal:  Vaccine       Date:  2007-03-12       Impact factor: 3.641

10.  Vaccines against pandemic influenza.

Authors:  Richard W Dutton; Susan L Swain; David L Woodland
Journal:  Viral Immunol       Date:  2007       Impact factor: 2.257

View more
  9 in total

1.  Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics.

Authors:  Jianqiang Zhou; Shun Xu; Jun Ma; Wen Lei; Kang Liu; Qiliang Liu; Yida Ren; Chunyi Xue; Yongchang Cao
Journal:  Virus Genes       Date:  2013-11-23       Impact factor: 2.332

2.  Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice.

Authors:  Maria E Lorenzo; Andrea Hodgson; Dionne P Robinson; Jenifer B Kaplan; Andrew Pekosz; Sabra L Klein
Journal:  Vaccine       Date:  2011-10-06       Impact factor: 3.641

3.  Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs.

Authors:  Ning Yang; James S Gibbs; Heather D Hickman; Glennys V Reynoso; Arun K Ghosh; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2016-03-25       Impact factor: 5.422

Review 4.  Cellular networks involved in the influenza virus life cycle.

Authors:  Tokiko Watanabe; Shinji Watanabe; Yoshihiro Kawaoka
Journal:  Cell Host Microbe       Date:  2010-06-25       Impact factor: 21.023

Review 5.  Mechanisms of sex disparities in influenza pathogenesis.

Authors:  Sabra L Klein; Andrea Hodgson; Dionne P Robinson
Journal:  J Leukoc Biol       Date:  2011-11-30       Impact factor: 4.962

6.  The cholesterol recognition/interaction amino acid consensus motif of the influenza A virus M2 protein is not required for virus replication but contributes to virulence.

Authors:  Shaun M Stewart; Wai-Hong Wu; Erin N Lalime; Andrew Pekosz
Journal:  Virology       Date:  2010-07-24       Impact factor: 3.616

7.  Palmitoylation of the influenza A virus M2 protein is not required for virus replication in vitro but contributes to virus virulence.

Authors:  Michael L Grantham; Wai-Hong Wu; Erin N Lalime; Maria E Lorenzo; Sabra L Klein; Andrew Pekosz
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  Influenza virus assays based on virus-inducible reporter cell lines.

Authors:  Yunsheng Li; Audrey Larrimer; Teresa Curtiss; Jaekyung Kim; Abby Jones; Heather Baird-Tomlinson; Andrew Pekosz; Paul D Olivo
Journal:  Influenza Other Respir Viruses       Date:  2009-09       Impact factor: 4.380

9.  A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time.

Authors:  Gilberto Gonzàlez-Parra; Filip De Ridder; Dymphy Huntjens; Dirk Roymans; Gabriela Ispas; Hana M Dobrovolny
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.